We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Read MoreHide Full Article
Key Takeaways
Myriad Genetics announced that The Lancet published a study on its Precise MRD in oligometastatic ccRCC.
The Phase 2 trial linked ctDNA levels with response to metastasis-directed radiation therapy.
Precise MRD detected ctDNA even in low tumor burden patients, enabling treatment de-escalation.
Myriad Genetics, Inc. (MYGN - Free Report) recently announced that The Lancet Oncology has published a study demonstrating the performance of the company’s Precise MRD in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).
The latest development is expected to bolster the company’s Oncology business.
MYGN Stock Movement Following the News
Following the news, shares of MYGN declined 2.7% to $6.61 last Friday.
Myriad Genetics’ growth strategy for its Oncology business focuses on expanding companion diagnostics, driving market growth through new clinical guidelines, and introducing new offerings. We expect the latest development to boost the market sentiment toward MYGN stock in the upcoming days.
The company currently has a market capitalization of $615.02 million. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 210%.
About MYGN’s Phase 2 Trial
The Phase 2 trial of metastasis-directed radiotherapy without systemic therapy (MRWS) for oligometastatic ccRCC and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker was an investigator-initiated single-arm trial enrolling patients with ccRCC and up to five metastases (NCT03575611). The study is among the largest trials conducted to date in this setting and includes one of the longest follow-up periods evaluating sequential metastasis-directed therapy without systemic therapy for ccRCC. The Precise MRD Test was used to evaluate ctDNA levels as part of an exploratory endpoint to determine the association of translational biomarkers with patient outcomes.
About MYGN’s Precise MRD Test
The Precise MRD Test is a tumor-informed, whole genome sequencing (WGS) based test that monitors hundreds to thousands of tumor-specific variants, enabling exceptional sensitivity and quantification of ctDNA in the blood of patients with cancer.
Key Findings From the Phase 2 trial
The study demonstrated that circulating tumor DNA (ctDNA) levels were associated with patients’ response to metastasis-directed radiation therapy (MDT). Precise MRD was able to detect ctDNA levels in patients with very low tumor burden. This may allow patients who are candidates for metastasis-directed radiotherapy without systemic therapy (MRWS) to delay or avoid systemic treatments, sparing them from serious side effects and supporting treatment de-escalation.
Additionally, 94% of patients tested at baseline had ctDNA levels below 100 ppm, which falls in the ultrasensitive testing range. Those who tested positive with Precise MRD prior to MRWS progressed to systemic therapy within a median time of 27 months, whereas those who tested negative were maintained on MDT for a median time of 54 months. In those who were ctDNA negative and maintained on MDT, overall survival was not compromised, with survival rates of 94% at two years and 87% at three years.
Image Source: Zacks Investment Research
Industry Prospects Favor MYGN
Per a Grand View Research report, the global MRD testing market size is projected to reach $4.50 billion by 2030, at a CAGR of 10.1% from 2025 to 2030. The market growth is driven by rising cancer incidence and prevalence, technological advancements in diagnostic tools, and integration with personalized medicines.
Another Development by MYGN
Last week, Myriad Genetics published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over treatment-as-usual (TAU). The large-scale data analysis, along with merging data from many independent studies, is evident of the clinical utility of the GeneSight Psychotropic test for patients with major depressive disorder (MDD) who have experienced at least one treatment failure.
MYGN Stock Price Performance
In the past year, MYGN’s shares have lost 75.5% compared with the industry’s decline of 11.1%.
MYGN’s Zacks Rank and Key Picks
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
Shares of Envista have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Medpace’s shares have rallied 31.3% in the past year. MEDP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.9%. It has a historical EPS growth rate of 30.9% compared with the industry’s 0.6%.
Shares of Phibro have jumped 29.1% in the past year against the industry’s 14% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. It has an earnings yield of 6.3% compared to the industry -0.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Key Takeaways
Myriad Genetics, Inc. (MYGN - Free Report) recently announced that The Lancet Oncology has published a study demonstrating the performance of the company’s Precise MRD in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).
The latest development is expected to bolster the company’s Oncology business.
MYGN Stock Movement Following the News
Following the news, shares of MYGN declined 2.7% to $6.61 last Friday.
Myriad Genetics’ growth strategy for its Oncology business focuses on expanding companion diagnostics, driving market growth through new clinical guidelines, and introducing new offerings. We expect the latest development to boost the market sentiment toward MYGN stock in the upcoming days.
The company currently has a market capitalization of $615.02 million. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 210%.
About MYGN’s Phase 2 Trial
The Phase 2 trial of metastasis-directed radiotherapy without systemic therapy (MRWS) for oligometastatic ccRCC and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker was an investigator-initiated single-arm trial enrolling patients with ccRCC and up to five metastases (NCT03575611). The study is among the largest trials conducted to date in this setting and includes one of the longest follow-up periods evaluating sequential metastasis-directed therapy without systemic therapy for ccRCC. The Precise MRD Test was used to evaluate ctDNA levels as part of an exploratory endpoint to determine the association of translational biomarkers with patient outcomes.
About MYGN’s Precise MRD Test
The Precise MRD Test is a tumor-informed, whole genome sequencing (WGS) based test that monitors hundreds to thousands of tumor-specific variants, enabling exceptional sensitivity and quantification of ctDNA in the blood of patients with cancer.
Key Findings From the Phase 2 trial
The study demonstrated that circulating tumor DNA (ctDNA) levels were associated with patients’ response to metastasis-directed radiation therapy (MDT). Precise MRD was able to detect ctDNA levels in patients with very low tumor burden. This may allow patients who are candidates for metastasis-directed radiotherapy without systemic therapy (MRWS) to delay or avoid systemic treatments, sparing them from serious side effects and supporting treatment de-escalation.
Additionally, 94% of patients tested at baseline had ctDNA levels below 100 ppm, which falls in the ultrasensitive testing range. Those who tested positive with Precise MRD prior to MRWS progressed to systemic therapy within a median time of 27 months, whereas those who tested negative were maintained on MDT for a median time of 54 months. In those who were ctDNA negative and maintained on MDT, overall survival was not compromised, with survival rates of 94% at two years and 87% at three years.
Image Source: Zacks Investment Research
Industry Prospects Favor MYGN
Per a Grand View Research report, the global MRD testing market size is projected to reach $4.50 billion by 2030, at a CAGR of 10.1% from 2025 to 2030. The market growth is driven by rising cancer incidence and prevalence, technological advancements in diagnostic tools, and integration with personalized medicines.
Another Development by MYGN
Last week, Myriad Genetics published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over treatment-as-usual (TAU). The large-scale data analysis, along with merging data from many independent studies, is evident of the clinical utility of the GeneSight Psychotropic test for patients with major depressive disorder (MDD) who have experienced at least one treatment failure.
MYGN Stock Price Performance
In the past year, MYGN’s shares have lost 75.5% compared with the industry’s decline of 11.1%.
MYGN’s Zacks Rank and Key Picks
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Envista (NVST - Free Report) , Medpace (MEDP - Free Report) and Phibro Animal Health (PAHC - Free Report) . Envista, Boston Scientific and IDEXX Laboratories carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Envista have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Medpace’s shares have rallied 31.3% in the past year. MEDP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.9%. It has a historical EPS growth rate of 30.9% compared with the industry’s 0.6%.
Shares of Phibro have jumped 29.1% in the past year against the industry’s 14% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. It has an earnings yield of 6.3% compared to the industry -0.3%.